doxazosin has been researched along with Obesity in 3 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 9.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| "We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 5.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
| "Obesity was associated with increased prostate volume and lower urinary tract symptoms." | 1.37 | Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. ( Chung, BH; Chung, MS; Lee, SH; Oh, CY; Park, KK; Yoo, SJ, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SH | 1 |
| Oh, CY | 1 |
| Park, KK | 1 |
| Chung, MS | 1 |
| Yoo, SJ | 1 |
| Chung, BH | 1 |
| Ueshiba, H | 1 |
| Miyachi, Y | 1 |
| Wofford, MR | 1 |
| Anderson, DC | 1 |
| Brown, CA | 1 |
| Jones, DW | 1 |
| Miller, ME | 1 |
| Hall, JE | 1 |
2 trials available for doxazosin and Obesity
| Article | Year |
|---|---|
Effect of doxazosin on insulin resistance in hypertensive patients with obesity.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Doxazosin; Female; Humans | 2003 |
Antihypertensive effect of alpha- and beta-adrenergic blockade in obese and lean hypertensive subjects.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure Monitorin | 2001 |
1 other study available for doxazosin and Obesity
| Article | Year |
|---|---|
Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients.
Topics: Adrenergic alpha-1 Receptor Antagonists; Body Mass Index; Case-Control Studies; Doxazosin; Humans; M | 2011 |